CL2011000516A1 - Compuestos heterociclos espiro tetracondensados, modulares de la ctividad de la beta-secretasa; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles en el tratamiento de la enfermedad de alzheimer. - Google Patents
Compuestos heterociclos espiro tetracondensados, modulares de la ctividad de la beta-secretasa; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles en el tratamiento de la enfermedad de alzheimer.Info
- Publication number
- CL2011000516A1 CL2011000516A1 CL2011000516A CL2011000516A CL2011000516A1 CL 2011000516 A1 CL2011000516 A1 CL 2011000516A1 CL 2011000516 A CL2011000516 A CL 2011000516A CL 2011000516 A CL2011000516 A CL 2011000516A CL 2011000516 A1 CL2011000516 A1 CL 2011000516A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- disease
- alzheimer
- beta
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Compuestos derivados de anillos espiro-tricíclicos, moduladores de beta-secretasas; proceso de preparación; composición farmacéutica; y su uso para el tratamiento de la enfermedad de Alzheimer, el deterioro cognitivo, demencia asociada con la enfermedad de Parkinson, entre otras.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9608208P | 2008-09-11 | 2008-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011000516A1 true CL2011000516A1 (es) | 2011-08-26 |
Family
ID=41319591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011000516A CL2011000516A1 (es) | 2008-09-11 | 2011-03-10 | Compuestos heterociclos espiro tetracondensados, modulares de la ctividad de la beta-secretasa; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles en el tratamiento de la enfermedad de alzheimer. |
Country Status (21)
Country | Link |
---|---|
US (1) | US8426447B2 (es) |
EP (1) | EP2328903B1 (es) |
JP (1) | JP5579720B2 (es) |
KR (1) | KR20110073511A (es) |
CN (1) | CN102209721A (es) |
AU (1) | AU2009291602B2 (es) |
BR (1) | BRPI0918449A2 (es) |
CA (1) | CA2736130C (es) |
CL (1) | CL2011000516A1 (es) |
CO (1) | CO6362014A2 (es) |
CR (1) | CR20110134A (es) |
EA (1) | EA201100461A1 (es) |
ES (1) | ES2459195T3 (es) |
IL (1) | IL211440A0 (es) |
MA (1) | MA32705B1 (es) |
MX (1) | MX2011002705A (es) |
MY (1) | MY148558A (es) |
PE (1) | PE20110805A1 (es) |
TW (1) | TWI385175B (es) |
WO (1) | WO2010030954A1 (es) |
ZA (1) | ZA201102674B (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
EP2801570A1 (en) | 2009-03-13 | 2014-11-12 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
WO2011106414A1 (en) | 2010-02-24 | 2011-09-01 | Dillard Lawrence W | Inhibitors of beta-secretase |
AU2011227511B2 (en) * | 2010-03-15 | 2014-02-20 | Amgen Inc. | Spiro-tetracyclic ring compounds as Beta - secretase modulators |
AU2011227501B9 (en) * | 2010-03-15 | 2013-08-22 | Amgen Inc. | Amino -dihydrooxazine and amino - dihydrothiazine spiro compounds as Beta - secretase modulators and their medical use |
WO2011130741A1 (en) * | 2010-04-16 | 2011-10-20 | Array Biopharma Inc. | Compounds for treating neurodegenerative diseases |
EP2601197B1 (en) * | 2010-08-05 | 2014-06-25 | Amgen Inc. | Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use |
EP2609081A1 (en) | 2010-08-23 | 2013-07-03 | Amgen Inc. | Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes |
EP2644607A4 (en) | 2010-11-22 | 2014-05-28 | Idemitsu Kosan Co | OXYGENIC FUSIONED RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT THEREWITH |
AR083953A1 (es) * | 2010-11-22 | 2013-04-10 | Array Biopharma Inc | Compuestos para tratar enfermedades neurodegenerativas |
US8957083B2 (en) | 2010-11-23 | 2015-02-17 | Amgen Inc. | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use |
US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
WO2012109165A1 (en) | 2011-02-07 | 2012-08-16 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use |
EP2675810A1 (en) | 2011-02-15 | 2013-12-25 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
EP2694489B1 (en) | 2011-04-07 | 2017-09-06 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
WO2012138590A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
EP2718287A1 (en) | 2011-06-07 | 2014-04-16 | F.Hoffmann-La Roche Ag | [1,3]oxazines |
RU2014111055A (ru) | 2011-08-22 | 2015-09-27 | Мерк Шарп И Доум Корп. | 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение |
JP2014526560A (ja) | 2011-09-21 | 2014-10-06 | アムジエン・インコーポレーテツド | β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法 |
US9650336B2 (en) | 2011-10-10 | 2017-05-16 | Astrazeneca Ab | Mono-fluoro beta-secretase inhibitors |
TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β-分泌酶抑制劑 |
EP2650284A1 (en) * | 2012-04-10 | 2013-10-16 | Merz Pharma GmbH & Co. KGaA | Heterocyclic derivatives as metabotropic glutamate receptor modulators |
AU2013267555A1 (en) * | 2012-05-30 | 2014-12-04 | Comentis, Inc. | Chromane compounds |
US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US9000182B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US10548882B2 (en) | 2012-06-21 | 2020-02-04 | Astrazeneca Ab | Camsylate salt |
TW201422592A (zh) | 2012-08-27 | 2014-06-16 | Boehringer Ingelheim Int | β-分泌酶抑制劑 |
JP2015532282A (ja) | 2012-09-28 | 2015-11-09 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | β−セクレターゼの阻害剤 |
US9725469B2 (en) | 2012-11-15 | 2017-08-08 | Amgen, Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
WO2016126726A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors |
WO2016126721A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | 3-aryl-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2683718A (en) * | 1952-01-11 | 1954-07-13 | Searle & Co | Spiro-[xanthene-9, 4'-imidazolidine]-2, 5-dione |
US3185696A (en) * | 1959-03-12 | 1965-05-25 | Jack M Tien | 3', 6'-diaminofluoran derivatives of gamma-lactam |
FR2576178B1 (fr) | 1985-01-24 | 1987-04-17 | Furodet Philippe | Procede de fabrication pour un enfumoir a chargement par-dessous |
DE3601492A1 (de) | 1986-01-20 | 1987-07-23 | Vacuumschmelze Gmbh | Verfahren zur herstellung eines stabilisierten filament-supraleiters mit hohem anteil an stabilisierungsmaterial |
US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
SI9300303A (en) | 1993-06-08 | 1994-12-31 | Krka Tovarna Zdravil | Process for isolation of hypolipemic effective substance |
WO1996040885A2 (en) | 1995-06-07 | 1996-12-19 | Athena Neurosciences, Inc. | β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION |
KR20070013361A (ko) | 1998-09-24 | 2007-01-30 | 파마시아 앤드 업존 캄파니 엘엘씨 | 알츠하이머병 세크레타제 |
MY138097A (en) | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
CN1217920C (zh) | 2000-06-30 | 2005-09-07 | 艾兰制药公司 | 治疗早老性痴呆的化合物 |
US7196163B2 (en) | 2001-05-22 | 2007-03-27 | Merk & Co., Inc. | Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity |
BR0210721A (pt) | 2001-06-27 | 2004-07-20 | Elan Pharm Inc | Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição |
KR100713137B1 (ko) | 2001-06-28 | 2007-05-02 | 동화약품공업주식회사 | 신규의 2,4-디플루오로벤즈아미드 유도체 |
US6864290B2 (en) | 2001-07-10 | 2005-03-08 | Pharmacia & Upjohn, Llp | Statine derivatives for the treatment of Alzheimer's disease |
US7067542B2 (en) | 2001-07-10 | 2006-06-27 | Pharmacia & Upjohn Company | Diaminediols for the treatment of Alzheimer's disease |
US20030109559A1 (en) | 2001-07-11 | 2003-06-12 | Andrea Gailunas | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds |
BR0213139A (pt) | 2001-10-04 | 2004-08-10 | Elan Pharm Inc | Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica |
EP1434580A2 (en) | 2001-10-05 | 2004-07-07 | Elan Pharmaceuticals, Inc. | Allylamides useful in the treatment of alzheimer's disease |
CA2465316A1 (en) | 2001-10-29 | 2003-05-08 | James P. Beck | Hydroxy substituted amides for the treatment of alzheimer's disease |
EA200400648A1 (ru) | 2001-11-08 | 2005-04-28 | Элан Фармасьютикалз, Инк. | N, n'-замещенные производные 1,3-диамино-2-гидроксипропана |
AR037460A1 (es) | 2001-11-30 | 2004-11-10 | Smithkline Beecham Plc | Compuesto de hidroxietileno, composicion farmaceutica que lo comprende, uso del mismo para la fabricacion de un medicamento y procedimiento para su preparacion |
US7312360B2 (en) | 2001-12-06 | 2007-12-25 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamines |
BR0306724A (pt) | 2002-01-04 | 2006-04-11 | Elan Pharm Inc | carboxamidas amino substituìdas para tratamento de doença de alzheimer |
MXPA04006882A (es) | 2002-01-17 | 2004-12-06 | Neurogen Corp | Analogos substituidos de quinazolin-4-ilamina como moduladores de receptores de capsaicina. |
AU2003276047A1 (en) | 2002-06-17 | 2003-12-31 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
US7115652B2 (en) | 2002-06-17 | 2006-10-03 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
PL374999A1 (en) | 2002-06-20 | 2005-11-14 | Pharmacia & Upjohn Company Llc | Process for preparing 5-(1, 3-oxazol-2-yl) benzoic acid derivatives |
UY27967A1 (es) | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
ATE443043T1 (de) | 2002-11-12 | 2009-10-15 | Merck & Co Inc | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer |
GB0228410D0 (en) | 2002-12-05 | 2003-01-08 | Glaxo Group Ltd | Novel Compounds |
CA2512111A1 (en) | 2003-01-07 | 2004-07-29 | Merck And Co., Inc. | Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease |
GB0305918D0 (en) | 2003-03-14 | 2003-04-23 | Glaxo Group Ltd | Novel compounds |
KR20050109990A (ko) | 2003-03-14 | 2005-11-22 | 머크 샤프 앤드 돔 리미티드 | 경증 인지 장애의 치료 및 알츠하이머 질환의 예방 또는지연 방법 |
WO2004094413A1 (en) | 2003-04-21 | 2004-11-04 | Elan Pharmaceuticals, Inc. | Phenacyl 2-hydroxy-3-diaminoalkanes |
WO2004094384A2 (en) | 2003-04-21 | 2004-11-04 | Elan Pharmaceuticals, Inc. | (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer’s disease |
EP1641748B1 (en) | 2003-06-30 | 2013-08-28 | Merck Sharp & Dohme Corp. | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease |
JP2007522088A (ja) | 2003-07-01 | 2007-08-09 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病の治療用フェニルカルボン酸ベータセクレターゼ阻害剤 |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
RS52883B (en) | 2003-12-15 | 2014-02-28 | Merck Sharp & Dohme Corp. | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
GB0402143D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
JP2007530696A (ja) | 2004-03-30 | 2007-11-01 | メルク エンド カムパニー インコーポレーテッド | アスパラギン酸プロテアーゼ阻害剤として有用な2−アミノチアゾール化合物 |
DE602005017033D1 (de) | 2004-06-16 | 2009-11-19 | Wyeth Corp | Amino-5,5-diphenylimidazolon-derivate zur beta-sekretase-hemmung |
JP2008516945A (ja) | 2004-10-15 | 2008-05-22 | アストラゼネカ・アクチエボラーグ | 置換されたアミノ化合物およびそれらの使用 |
BRPI0606690A2 (pt) | 2005-01-14 | 2009-07-14 | Wyeth Corp | composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica |
US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
EP1896406A2 (en) | 2005-06-14 | 2008-03-12 | Shering Corporation | The preparation and use of compounds as protease inhibitors |
EP2345411B1 (en) | 2005-06-14 | 2013-10-02 | Merck Sharp & Dohme Corp. | Heterocyclic aspartyl protease inhibitors, preparation and use thereof |
EP1896467B1 (en) * | 2005-06-16 | 2010-12-01 | Janssen Pharmaceutica NV | Tricyclic opioid modulators |
TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
WO2007009014A2 (en) * | 2005-07-13 | 2007-01-18 | Raviv Laor | Personal topical disinfectant device |
US8211904B2 (en) | 2005-07-18 | 2012-07-03 | Merck, Sharp & Dohme Corp. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
KR20080050430A (ko) | 2005-09-26 | 2008-06-05 | 와이어쓰 | 베타-세크레타제 (bace) 억제제로서아미노-5-[4-(디플루오로메톡시)페닐]-5-페닐이미다졸론화합물 |
CA2628074C (en) | 2005-10-25 | 2014-01-14 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivative |
WO2007100536A1 (en) * | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
US20090099217A1 (en) | 2006-04-05 | 2009-04-16 | Astex Therapeutics Ltd. | 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies |
TW200808751A (en) | 2006-04-13 | 2008-02-16 | Astrazeneca Ab | New compounds |
US8168641B2 (en) | 2006-06-12 | 2012-05-01 | Schering Corporation | Aspartyl protease inhibitors |
TW200815447A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds IV |
TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
CA2668065A1 (en) | 2006-10-30 | 2008-05-08 | Merck & Co., Inc. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
TW200831091A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
TW200831484A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
KR101275405B1 (ko) | 2007-02-02 | 2013-06-17 | 에프. 호프만-라 로슈 아게 | 중추 신경계 장애의 치료용 taar1 리간드로서 2-아미노옥사졸린 |
PE20090617A1 (es) | 2007-03-23 | 2009-05-08 | Wyeth Corp | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa |
CA2683887A1 (en) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group having inhibitory activity against production of amyloid beta protein |
EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
TW200902503A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
DK2233474T3 (en) | 2008-01-18 | 2015-10-19 | Eisai R&D Man Co Ltd | Concentrated aminodihydrothiazinderivat |
MX2010008347A (es) | 2008-02-18 | 2010-11-12 | Hoffmann La Roche | Derivados de 4,5-dihidro-oxazol-2-ilamina. |
BRPI0911356A2 (pt) | 2008-04-22 | 2019-09-24 | Schering Corp | compositos de 2-imino-3-metil pirrol pirimidina substituída por fenila como inibidores de bace-1, composições, e seu uso |
TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Bace抑制劑 |
PE20110215A1 (es) | 2008-07-24 | 2011-03-31 | Hoffmann La Roche | Derivados de 4,5-dihidro-oxazol-2-ilo |
EP2318416B1 (en) * | 2008-07-28 | 2013-09-04 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
-
2009
- 2009-09-11 BR BRPI0918449A patent/BRPI0918449A2/pt not_active IP Right Cessation
- 2009-09-11 JP JP2011527012A patent/JP5579720B2/ja not_active Expired - Fee Related
- 2009-09-11 CN CN2009801456428A patent/CN102209721A/zh active Pending
- 2009-09-11 KR KR1020117008316A patent/KR20110073511A/ko not_active Application Discontinuation
- 2009-09-11 AU AU2009291602A patent/AU2009291602B2/en not_active Ceased
- 2009-09-11 WO PCT/US2009/056748 patent/WO2010030954A1/en active Application Filing
- 2009-09-11 PE PE2011000606A patent/PE20110805A1/es not_active Application Discontinuation
- 2009-09-11 TW TW098130795A patent/TWI385175B/zh not_active IP Right Cessation
- 2009-09-11 MY MYPI2011001092A patent/MY148558A/en unknown
- 2009-09-11 EP EP09737222.1A patent/EP2328903B1/en active Active
- 2009-09-11 MX MX2011002705A patent/MX2011002705A/es active IP Right Grant
- 2009-09-11 US US12/558,426 patent/US8426447B2/en active Active
- 2009-09-11 CA CA2736130A patent/CA2736130C/en not_active Expired - Fee Related
- 2009-09-11 EA EA201100461A patent/EA201100461A1/ru unknown
- 2009-09-11 ES ES09737222.1T patent/ES2459195T3/es active Active
-
2011
- 2011-02-27 IL IL211440A patent/IL211440A0/en unknown
- 2011-03-10 CL CL2011000516A patent/CL2011000516A1/es unknown
- 2011-03-14 CR CR20110134A patent/CR20110134A/es unknown
- 2011-03-25 CO CO11036742A patent/CO6362014A2/es not_active Application Discontinuation
- 2011-04-11 ZA ZA2011/02674A patent/ZA201102674B/en unknown
- 2011-04-11 MA MA33762A patent/MA32705B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
CA2736130A1 (en) | 2010-03-18 |
WO2010030954A1 (en) | 2010-03-18 |
US8426447B2 (en) | 2013-04-23 |
PE20110805A1 (es) | 2011-11-09 |
ZA201102674B (en) | 2011-12-28 |
EP2328903B1 (en) | 2014-03-05 |
JP5579720B2 (ja) | 2014-08-27 |
TW201022280A (en) | 2010-06-16 |
BRPI0918449A2 (pt) | 2019-09-24 |
KR20110073511A (ko) | 2011-06-29 |
AU2009291602A1 (en) | 2010-03-18 |
MA32705B1 (fr) | 2011-10-02 |
JP2012502112A (ja) | 2012-01-26 |
MX2011002705A (es) | 2011-09-09 |
CN102209721A (zh) | 2011-10-05 |
CR20110134A (es) | 2011-08-04 |
EP2328903A1 (en) | 2011-06-08 |
CA2736130C (en) | 2014-01-14 |
MY148558A (en) | 2013-04-30 |
US20100087429A1 (en) | 2010-04-08 |
AU2009291602B2 (en) | 2013-02-14 |
TWI385175B (zh) | 2013-02-11 |
CO6362014A2 (es) | 2012-01-20 |
ES2459195T3 (es) | 2014-05-08 |
EA201100461A1 (ru) | 2011-10-31 |
IL211440A0 (en) | 2011-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011000516A1 (es) | Compuestos heterociclos espiro tetracondensados, modulares de la ctividad de la beta-secretasa; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles en el tratamiento de la enfermedad de alzheimer. | |
CL2012001955A1 (es) | Compuestos derivados biciclicos de triazol sustituidos, moduladores de gamma secretasa; composicion farmaceutica que los comprende; utiles en el tratamiento o la prevencion de enfermedad de alzheimer, demencia, demencia asociada con la enfermedad de parkinson, entre otras. | |
DOP2011000176A (es) | Compuestos organicos | |
CL2008003593A1 (es) | Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer | |
CL2008002162A1 (es) | Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras. | |
CL2008001914A1 (es) | Compuestos heterociclicos de nitrogeno y oxigeno,moduladores de gama secretasa, composicion farmaceutica de dichos compuestos; kit farmaceutico y su uso para prevenir o tratar enfermedades asociadas al sistema nervioso central como alzheimer, sindrome de down, enfermedades neurodegenerativas, inhibir el deposito de proteina amiloide. | |
CL2008001560A1 (es) | Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico. | |
ECSP099720A (es) | Moduladores de gamma-secretasa | |
CL2008002809A1 (es) | Compuestos derivados de cianoisoquinolina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una adiccion a las drogas, en el tratamiento de un trastorno neurodegenerativo, como alzheimer, parkinson, demencia, entre otros. | |
CL2009000161A1 (es) | Compuestos derivados de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol; composicion farmaceutica que los comprende; uso en el tratamiento de trastornos neurodegenerativos, cognitivos o psicoticos, enfermedad de alzheimer, entre otros; y un kit que contiene a los compuestos. | |
CL2012001762A1 (es) | Compuestos derivados de pirazina, con actividad inhibidora de bace; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de enfermedad de alzheimer o deterioro cognitivo leve. | |
CL2007001885A1 (es) | Compuestos derivados de urea de tropano, moduladores de la actividad de la 11betahsd1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como obesidad, diabetes, hipertension, aterosclerosis, demencia y osteoporosis. | |
UY31673A1 (es) | "derivados heterocíclicos de urea y métodos de uso de los mismos-211" | |
CL2013000380A1 (es) | Compuestos heterociclicos derivados de [1,2,4] tiadiazina, moduladores positivos del receptor de ampa; medicamento que los contiene; y su uso para la prevencion o el tratamiento de depresion, enfermedad de alzheimer, esquizofrenia o trastorno de hiperactividad de deficit de atencion. | |
CL2008003116A1 (es) | Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras. | |
CL2009000990A1 (es) | Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras. | |
ECSP088402A (es) | Compuestos y composiciones que contienen diarilamina, y su utilización como moduladores de los receptores c-kit | |
CL2008002308A1 (es) | Compuestos heterociclos, moduladores de beta secretasa; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos utiles para reducir la produccion de beta amiloide; y kit que contiene a uno de los compuestos, utiles para tratar enfermedades neurodegenerativas, tal como alzheimer. | |
CL2009000889A1 (es) | Compuestos derivados de 2-oxo-2,5-dihidro pirrol propionamida, activadores de glucoquinasa; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compestos; y su uso en el tratamiento de diabetes mellitus. | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
ECSP099451A (es) | Compuestos de urea policíclicos antibacterianos | |
CL2013002511A1 (es) | Compuestos derivados de 3,4-dihidropirrolo[1,2-a]pirazin-1-ilamina, inhibidores de (bace); composicion farmaceutica que los comprende; proceso de preparacion; util para el tratamiento o prevencion de la enfermedad de alzheimer, demencia, sindrome de down y otras demencias asociadas con beta-amiloides. | |
CL2008002876A1 (es) | Compuestos derivados de heterociclo sustituidos, moduladores de gamma-secretasa; composicion farmaceutica que los comprende; uso en el tratamiento de enfermedades neurodegenerativas como alzheimer o sindrome de down. | |
CL2011001098A1 (es) | Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras. | |
CU24177B1 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 |